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Background: Bronchial asthma is usually associated with high sputum eosinophil levels. However, recent reports have suggested the 
importance of noneosinophilic asthma (NEA) as a distinct phenotype of asthma. 
Objective: The aim of this study was to evaluate clinical significance of sputum eosinophilia and long-term treatment outcomes 
related to sputum eosinophilia in Korean asthmatics.
Methods: A total of 201 steroid-naive asthmatics who had undergone induced sputum analysis at baseline were selected from the 
Cohort for Reality and Evolution of Adult Asthma study population. Clinical evaluation, spirometry, a skin-prick test, a methacholine 
bronchial provocation test, and sputum eosinophil analysis were performed initially, and patients received the treatment 
recommended by the Global Initiative for Asthma. Lung function was evaluated every 6 months, and 53 patients completed 24 
months of regular follow-up visits. Sputum eosinophilia was defined as a sputum eosinophil count of >3%.
Results: Of the 201 steroid-naive asthmatics, 97 patients had NEA and 104 had eosinophilic asthma (EA). Only 52% of steroid-naive 
asthmatic subjects had elevated baseline sputum eosinophil levels. A higher percentage of sputum eosinophils was associated with 
a lower PC20 (r = –0.193; p = 0.009, Spearman correlation), but not with forced expiratory volume in one second (FEV1) (r = 0.045; p 
= 0.525). During the 24-month study period, the percentage change of FEV1 was significantly lower in the NEA group than in the EA 
group at 6, 12, 18, and 24 months (p < 0.05). The NEA group, unlike the EA group, showed no significant improvement in FEV1 at 6, 
12, 18, or 24 months (p > 0.05).
Conclusion: A higher sputum eosinophil percentage was correlated with a higher airway hyperresponsiveness. Compared with EA 
patients, NEA patients had poor treatment outcomes in the 2-year follow-up of a Korean asthma cohort population.
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INTRODUCTION
Asthma is regarded as a heterogeneous, chronic airway 
inflammatory disease comprising various phenotypes, and 
is characterized by reversible airway obstruction and airway 
hyperresponsiveness (AHR) [1]. Asthma phenotypes can be 
categorized by clinical features as well as by immunopathology on 
the basis of inflammation patterns, with regard to the existence or 
absence of particular inflammatory cell types such as eosinophils 
or neutrophils [1-3]. The identification of asthma phenotypes has 
potential clinical importance, because natural history, disease 
prognosis, and treatment response may differ according to 
phenotype [1, 2].
Eosinophils have long been believed to play a central role in 
asthmatic airway inflammation [4]. Early biopsy studies revealed 
eosinophilic inflammation within the airway mucosa of asthmatic 
patients [5]. The functional relevance of eosinophils is supported 
by studies demonstrating that eosinophilic airway inflammation 
was improved after inhaled corticosteroid treatment [6], was 
aggravated by allergen exposure [7], and was correlated with 
asthma severity [8]. However, as these studies were performed 
in small populations, they afford a limited representation of the 
general asthmatic population. 
The development of simple, noninvasive methods for assessing 
airway inflammation using induced sputum has provided a way of 
studying airway inflammation in a diverse range of patients [9, 10]. 
In many studies using these methods, sputum eosinophilia was 
not observed in a significant proportion of asthma patients [11-
13]. Sputum eosinophilia was not detected in as many as 25% of 
untreated symptomatic patients [11], patients with severe refractory 
asthma [13], and patients experiencing asthma exacerbation [12], 
and in up to 50% of patients taking high-dose inhaled steroids 
[14]. Noneosinophilic asthma (NEA) has been estimated to be 
present in 49% of patients with symptomatic asthma presenting 
to a respiratory clinic [15]. Furthermore, the absence of sputum 
eosinophilia was reported to be a stable feature in a number of 
patients over a 12-month period in a longitudinal study [16]. Based 
on these findings, recent reports have suggested the importance 
of NEA as a distinct phenotype of asthma [15, 17].
Studies have suggested that NEA is associated with increased 
neutrophil and interleukin (IL)-8 levels and that non-allergic, 
neutrophil-driven airway inflammation is the underlying 
mechanism for NEA [15]. The activation of an innate immune 
response provoked by endotoxins, viral or bacterial infections, 
cigarette smoke, air pollutants, or occupational agents has been 
linked with the pathogenesis of noneosinophilic, neutrophilic 
inflammation [15, 17]. From a clinical point of view, NEA is 
associated with smoking, obesity, and a poor response to an 
inhaled corticosteroid (ICS) [15, 17]. Although many studies have 
shown that low sputum eosinophil counts are associated with 
poor outcomes of ICS treatment, most were performed with short 
treatment durations and in limited populations [17]. To date, there 
is little information regarding the long-term treatment outcome 
of NEA. In addition, the clinical significance of the absence of 
sputum eosinophilia has not been fully explored in Korean 
symptomatic asthmatics. The purpose of the present study was 
to evaluate clinical significance of sputum eosinophilia and long-
term treatment responses of Korean asthmatics with and without 
sputum eosinophilia.
MATERIALS AND METHODS
Subjects
A total of 201 asthma patients who had undergone induced 
sputum analysis before regular asthma treatment were enrolled 
in this study. All were recruited from the previously established 
Cohort for Reality and Evolution of Adult Asthma (COREA) [18] 
according to the following inclusion criteria: (1) airway reversibility 
documented by an increase of forced expiratory volume in 
one second (FEV1) of 12% and 200 mL after inhalation of 200 
µg of salbutamol, or airway hyperresponsiveness documented 
by a methacholine provocation concentration causing a 20% 
fall in FEV1 (PC20) of ≤16 mg/mL, in the past or at the time of 
enrollment; (2) presence of persistent characteristic asthma 
symptoms and physician’s diagnosis of asthma; (3) availability of 
adequate induced sputum analysis data at the time of enrollment; 
and (4) absence of asthma controller medication, including 
systemic ICS, leukotriene antagonists, and theophylline, for at least 
3 months before enrollment and induced sputum analysis. Of the 
201 subjects, 53 completed 24 months of regular follow-up visits, 
and the analysis of long-term treatment outcomes was performed 
with this group. All subjects were provided written informed 
consent, and the study protocol was approved by the institutional 
review board of each participating hospital.
Study design
Clinical evaluation, spirometry, allergy skin-prick tests, a apallergy.org
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methacholine bronchial provocation test, blood tests, chest and 
paranasal sinus simple radiological exams, and sputum eosinophil 
analysis were performed initially at the time of enrollment. The 
subjects received treatment based on symptoms and lung 
function, according to the recommendations of the Global 
Initiative for Asthma [19]. Asthma symptom scores, presence of 
exacerbation, and treatment compliance were evaluated every 3 
months during the 24-month follow-up period. Lung function was 
evaluated at 6-month intervals, using spirometry equipment and 
techniques that conformed to the criteria issued by the American 
Thoracic Society and European Respiratory Society [20]. Skin-
prick tests were performed using 11 inhalant allergens (Bencard, 
UK; or Allergopharma, Germany), including Dermatophagoides 
pteronyssinus, D. farinae, tree pollen mixture, grass pollen mixture, 
ragweed, mugwort, cockroach, Alternaria, Aspergillus, cat, and 
dog. Wheal development 15 min later was used to assess positive 
responses to allergens. Atopy was defined as a positive skin-prick 
test response (allergen/histamine ratio ≥1 and mean wheal size >3 
mm) to one or more allergens.
Induced sputum analysis
Sputum induction and processing were carried out according 
to a standardized protocol, as previously described [21]. Briefly, 
after measurement of basal FEV1, all study participants were 
pretreated with 200 µg of salbutamol (Ventolin
TM; GlaxoSmithKline, 
England). To induce sputum production, a 4.5% hypertonic 
saline solution was administered for four times at 5-min intervals 
using an ultrasonic nebulizer (Omron, Japan) with the output set 
at 4.5 mL/min. The patients rinsed their mouths and carefully 
spit the sputum into a Petri dish. The more viscid and denser 
portions were selected and processed. After the addition of 
dithiothreitol (DTE, 0.01 M), the sputum samples were mixed by 
rotation for 20 min at room temperature and filtered through 52-
mm nylon gauze to remove debris and mucus. The cell pellets 
were collected by centrifugation at 450 × g for 10 min and 
resuspended in phosphate-buffered saline to a volume equal 
to that of the original sputum sample plus DTE. The cells were 
counted using a hemacytometer, and cell concentrations were 
adjusted to 1.0 × 10
6 cells/mL. Cytospins were prepared by adding 
60 µL of this cell suspension to Shandon II cytocentrifuge cups 
(Shandon Southern Instruments, USA) and were spun for 5 min at 
42 × g. Slides were prepared, and the cells were stained with Diff 
Quik solution (Sysmex, Japan). To determine cell differentiation, 
300 nucleated cells per slide were counted, and macrophage, 
lymphocyte, neutrophil, and eosinophil values were calculated 
as percentages of total inflammatory cells, excluding squamous 
epithelial cells. Sputum samples that contained more than 30% 
squamous epithelial cells were not analyzed. Subjects were 
classified as either NEA or eosinophilic asthma (EA) based on the 
initial sputum eosinophil count. NEA was defined as asthma with 
sputum eosinophil counts <3%, and EA was defined as asthma 
with sputum eosinophil counts of ≥3% [22].
Statistical analysis
All statistical analyses were performed using SPSS ver. 16.0 (SPSS, 
USA). Categorical data were compared using a chi-squared or 
Fisher’s exact test. Numerical data were compared using Student’s 
t-test or a Mann-Whitney test. Linear regression was applied to 
account for the effects of age, gender, body mass index (BMI), 
and smoking on changes in the pulmonary function test results. 
Differences in FEV1 and symptom scores over time within groups 
were assessed with a Wilcoxon matched-pair t-test. A value of p 
< 0.05 indicated statistical significance.
RESULTS
Clinical characteristics of 201 steroid-naive asthmatics
Of the 201 asthmatic patients included in the study, 97 (48.3%) 
were in the NEA group and 104 (51.7%) were in the EA group. 
Mean age was 51.2 years and 44.4% was male.
Of the 201 subjects, 53 completed 24 months of regular follow-
up visits and 148 did not complete the study. But no difference 
in age, gender, BMI or smoking habit was found between the 
followed-up patients and followed-up loss patients. There was 
no difference in the baseline FEV1, symptom duration, asthma 
severity, or prevalence of atopy, or allergic rhinosinusitis between 
the two groups (Table 1).
Relationship between sputum eosinophil/neutrophil profiles 
and lung function and airway hyperresponsiveness in steroid-
naive asthmatics
We evaluated the correlation between sputum inflammatory 
cell profiles and lung function and airway hyperresponsiveness 
in the steroid-naive state. Correlation analyses were performed 
using percentages of eosinophils and neutrophils in the induced 
sputum collected at baseline (Fig. 1). A higher percentage of 
sputum eosinophils was associated with a lower PC20 (r = –0.193; 
p = 0.009, Spearman correlation), but not with FEV1 (r = 0.045; p = apallergy.org
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Table 1. Comparison of demographic and sputum characteristics at inception between participants in follow-up study and non-participants
Variables Total patients
n = 201
Follow-up
patients
n = 53
Follow-up loss 
patients
n = 148
p-value*
Age (yr) 51.2 ± 15.8 50.0 ± 16.6 54.3 ± 13.3 0.066
Gender (% male) 44.4 56.6 52.8 0.633
BMI 24.4 ± 3.7 9.5 ± 15.7 5.7 ± 12.8 0.345
Smoking habit (never:former:current (%)) 53:31:16 18.2:30.8:51.0 8.2:32.7:59.2 0.242
Smoking (pack-years) 8.5 ± 15.1 9.5 ± 15.7 5.7 ± 12.8 0.108
Symptom duration (yr) 9.1 ± 10.7 8.4 ± 10.3 11.0 ± 11.5 0.130
Asthma severity (GINA step1/2/3/4) (%) 6.5/46.8/27.9/18.9 6.8/48.0/26.4/18.9 5.7/43.4/32.1/18.9 0.872
Cough (%) 75.5 78.2 67.9 0.135
Dyspnea (%) 64.5 67.3 56.6 0.161
Wheezing (%) 62.5 63.3 60.4 0.710
FEV1% 78.7 ± 21.9 78.8 ± 22.1 78.3 ± 21.7 0.868
PC20 (mg/mL) 5.4 ± 6.1 5.1 ± 5.8 6.2 ± 6.9 0.311
Allergic rhinosinusitis (%) 68.9 66.7 75.0 0.287
Atopy (%) 52.6 55.0 46.2 0.275
EA (%) 51.7 49.3 58.5 0.252
PC20: the provocative concentration of methacholine was ≤ 25 mg/mL causing a 20% fall in forced expiratory volume in one second (FEV1).  
*Compared 
with parameters of followed-up patients and that of followed-up loss patients. 
Table 2. Baseline demographic characteristics of NEA and EA patients who completed 24 months of follow-up visits (n = 53)
Variables NEA patients
n = 22
EA patients
n = 31 p-value
Age (yr) 55.0 ± 14.4 53.8 ± 12.8 0.767
Gender (% male) 40.9 51.6 0.442
BMI (kg/m
2) 24.7 ± 3.4 23.5 ± 3.1 0.198
Smoking habit (never/former/current (%)) 71.4/19.0/9.5 50.0/42.9/7.1 0.212
Smoking (pack-years) 3.1 ± 7.0 7.7 ± 15.8 0.205
Symptom duration (yr) 11.9 ± 12.3 10.4 ± 11.1 0.637
Cough (%) 63.6 71.0 0.573
Dyspnea (%) 54.5 58.1 0.799
Wheezing (%) 54.5 64.5 0.465
Asthma severity  (GINA step1/2/3/4) (%) 4.5/50.0/36.4/9.1 6.5/38.7/27.0/25.8 0.461
Blood WBC counts (/μL) 7449.1 ± 1775.7 7552.7 ± 1934.7 0.844
Blood eosinophil counts (/μL) 227.6 ± 160.7 509.8 ± 345.9 <0.001
Serum total IgE 223.5 ± 269.7 276.8 ± 312.8 0.557
FEV1 % predicted 80.6 ± 15.8 76.6 ± 25.2 0.517
FVC % predicted 89.0 ± 16.4 89.7 ± 19.6 0.886
FEV1/FVC  71.6 ± 8.7 67.6 ± 12.7 0.205
PC20 (mg/mL) 7.9 ± 7.9 4.9 ± 5.7 0.137
Allergic rhinosinusitis (%) 73.7 75.9 0.865
Atopy (skin test) % 42.9 48.4 0.695
Initial treatment
ICS (%) 9.5 3.6 0.391
ICS + LABA (%) 90.5 96.4 0.390
Oral corticosteroid (%) 22.7 35.5 0.319
Dose of oral corticosteroid
* 12.5 ± 3.5 13.0 ± 6.9 0.892
Leukotriene modifier (%) 71.4 71.4 1.000
Theophylline (%) 9.5 28.6 0.099
NEA: noneosinophilic asthma, EA: eosinophilic asthma, ICS: inhaled corticosteroids, LABA: long-acting β2-agonist. 
*Equipotent daily dose of oral 
prednisolone, mg.apallergy.org
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0.525). The percentage of sputum neutrophils was not associated 
with either PC20 (r = 0.104, p = 0.143) or FEV1 (r = 0.003, p = 0.973). 
Clinical characteristics of NEA and EA in steroid-naive 
asthmatics who completed 24 months of follow-up visits
A total of 53 patients (22 NEA and 31 EA patients) who 
completed 24 months of follow-up visits were analyzed to 
compare long-term asthma treatment responses between 
the NEA and EA groups. No difference in age, gender, BMI or 
smoking habit was found between the NEA and EA groups. 
Baseline blood eosinophil counts were significantly lower and 
baseline blood neutrophil counts were significantly higher in the 
NEA group than in the EA group. There was no difference in the 
baseline FEV1 and FVC between the two groups and there was 
no significant difference in symptom duration, asthma severity, 
or allergic rhinosinusitis between the NEA and EA groups. Initial 
asthma medication use, including ICSs, long-acting β2-agonists, 
leukotriene antagonists, theophylline, and oral corticosteroids, was 
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Fig. 1. Correlation of sputum inflammatory cell profiles with lung function and airway hyperresponsiveness in steroid-naive asthma.
Table 3. Sputum differential cell counts within the total non-squamous cell count who completed 24 months of follow-up visits (n = 53)
Variables NEA patients EA patients p-value
macrophages, % 61.3 ± 35.5 46.9 ± 27.7 0.121
neutrophils, % 37.5 ± 35.2 24.8 ± 23.5 0.152
lymphocytes, % 0.7 ± 1.7 0.8 ± 1.9 0.808
eosinophils, % 0.6 ± 0.8 27.5 ± 26.5 <0.001apallergy.org
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FEV1 improvement in NEA and EA patients during the 
24-month follow-up period
Throughout the 24-month follow-up period, the improvement 
in FEV1 was less in NEA patients compared with EA patients, 
although the difference was statistically significant only at 12 (0.7 
± 11.1 vs. 25.3 ± 56.7, p = 0.048) and 18 months (3.1 ± 11.6 vs. 
18.3 ± 29.6, p = 0.021). However, after adjusting for the effects of 
demographic factors such as age, gender, BMI, and smoking habit, 
the improvement in FEV1 was significantly less in the NEA group 
than in the EA group at every 6-month visit during the 24-month 
follow-up (Table 4).
Changes in FEV1 over time in NEA and EA patients
We analyzed FEV1 of total of 53 patients (22 NEA and 31 EA 
patients) who completed 24 months of follow-up visits. The 
changes in FEV1 and symptom scores over time in each group 
were assessed using a Wilcoxon matched-pair t-test. EA patients 
showed significantly improved FEV1 at 6 months of treatment 
compared with the baseline FEV1 (82.2 ± 20.3% vs. 76.6 ± 25.2%, 
p = 0.002), and this improvement was sustained at 12, 18, and 24 
months (80.0 ± 20.2, 85.1 ± 22.6, and 83.6 ± 19.7%, respectively; 
p < 0.05). However, there was no improvement in FEV1 in NEA 
patients at any 6-month follow-up visit (82.9 ± 18.3, 78.5 ± 16.5, 
83.5 ± 16.2, 82.2 ± 18.3, and 81.6 ± 17.1%, respectively; p > 
0.05) (Fig. 2). Symptom scores improved in both groups, with no 
significant difference between the groups. The frequency of acute 
exacerbation was not significantly different between the groups 
(data not shown). 
also similar between the two groups (Table 2). 
Sputum differential cell counts within the total non-squamous 
cell count
As expected, the mean percentage of eosinophils (as the 
percentage of the total number of nonsquamous cells) in NEA 
patients was significantly lower than EA patients (0.6 ± 0.8 vs. 27.5 
± 26.5, p < 0.0001). No difference in sputum level of the mean 
percentage of neutrophils was found between NEA patients and 
EA patients (Table 3).
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Fig. 2. Changes in forced expiratory volume in one second (FEV1) 
with asthma treatment over a 24-month period in patients with 
noneosinophilic asthma and eosinophilic asthma. 
*p < 0.01, 
†p < 0.0001, 
‡p < 0.05 compared with baseline FEV1%.
Table 4. Comparison of changes in FEV1 between NEA and EA patients
NEA patients EA patients Adjusted
p-value*
6 months (N) 17 24
FEV1 % predicted 82.9 ± 18.3 82.2 ± 20.3 0.644
Change % of FEV1
†  5.3 ± 12.4 26.1 ± 50.6 0.025
12 mo (N) 20 24
FEV1, % predicted 78.5 ± 16.5 80.0 ± 20.2 0.521
Change % of FEV1
†  0.7 ± 11.1 25.3 ± 56.7 0.015
18 months (N) 19 27
FEV1 % predicted 83.5 ± 16.2 85.1 ± 22.6 0.720
Change % of FEV1
† 3.1 ± 11.6 18.3 ± 29.6 0.019
24 months (N) 22 31
FEV1, % predicted 81.6 ± 17.1 83.6 ± 19.7 0.672
Change % of FEV1
†  0.0 ± 10.6 17.9 ± 24.3 0.037
*p-value: adjusted with age, gender, BMI, and smoking by multiple linear regression. 
†Change % of FEV1: (follow-up FEV1 % predicted – baseline FEV1 % 
predicted)/baseline FEV1 % predicted. apallergy.org
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patients had significantly less improvement in FEV1, PC20, and 
visual analogue symptom scores after 2 months of inhaled 
budesonide treatment. A study by Bacci et al. [27] showed that 
low sputum eosinophil counts were associated with a lack of 
FEV1 improvement following 2-4 weeks of treatment with inhaled 
beclomethasone.
In a 2-week oral steroid trial in chronic stable asthmatics, Little 
et al. [28] found that sputum eosinophilia had a positive predictive 
value of 64% and negative predictive value of 68% (sensitivity 54%, 
specificity 76%) for an increase in FEV1 of ≥15% after treatment. 
Moreover, Meijer et al. [29] observed that sputum eosinophilia 
predicted the FEV1 response as well as PC20 and quality of life 
improvement after 2 weeks of corticosteroid treatment. 
Unlike previous studies using short courses of inhaled or 
systemic steroid treatment, our study was a 24-month, long-term 
observational study and showed no significant improvement in 
FEV1 in NEA patients. This study was not conducted with a fixed 
medication regimen over the study period; instead, our subjects 
were given controller medications, including at least an ICS, and 
were followed with adjustments of medications according to the 
guidelines. The medication pattern was similar between the EA and 
NEA groups. Despite guideline-based therapy, the NEA patients 
showed no significant lung function change at any of the follow-
up visits, whereas EA patients exhibited significantly improved 
FEV1 within 6 months, and the improvement was sustained for 24 
months. These results suggest that sputum eosinophilia may be 
a useful predictor of long-term response to asthma therapy and 
that current asthma controller medications, including ICSs, long-
acting β2-agonists, and leukotriene antagonists, are less effective in 
patients with NEA than in those with EA.
The pathogenesis of NEA involves the activation of an innate 
immune response and neutrophilic airway inflammation that 
generally tends to be unresponsive to steroids [15, 17, 30]. 
Environmental exposure to bacterial endotoxins, viruses, particulate 
air pollution, or ozone is an important trigger for neutrophilic 
airway inflammation [15]. Proinflammatory cytokines, including IL-
1, IL-8, and tumor necrosis factor a, together with Toll-like receptor 
and CD14 contribute to the development of noneosinophilic, 
neutrophilic inflammation in response to the activation of innate 
immunity [15, 17]. Recent reports have indicated that Th17 cells 
evoke neutrophilic airway inflammation and that Th17 cell–
mediated airway inflammation displays a more severe, steroid-
resistant asthma phenotype [31-33]. Our finding that NEA failed 
to show an improvement in FEV1 despite appropriate 24-month 
DISCUSSION
Our observational study showed that NEA patients had no 
significant lung function improvement during 24 months of 
guideline-based regular controller treatment. In contrast, EA 
patients experienced significant long-term FEV1 improvement and 
better treatment outcomes compared with NEA patients. 
Airway inflammation is the basis of asthma pathogenesis, and the 
goal of asthma treatment using ICSs is the targeted control of airway 
inflammation for optimal lung function and symptom control 
[19]. However, given the heterogeneous inflammatory processes 
involved in the pathogenesis of asthma, the clinical features and 
treatment responses of asthmatics can vary according to individual 
underlying inflammatory or immunological phenotypes [1, 2]. EA 
is well established as classical allergic asthma mediated by Th2 
cytokines, including IL-4, IL-5, and IL-13, that orchestrate eosinophilic 
airway inflammation and IgE production [3]. An increased sputum 
eosinophil percentage has been reported to be associated 
with more severe asthma, more severe airflow limitation, and 
increased airway hyperresponsiveness [8, 23, 24]. Nevertheless, 
studies using induced sputum analysis have revealed that not all 
patients with severe asthma have airway eosinophilia and that the 
noneosinophilic asthma phenotype is present across all grades of 
severity [13, 25].
In the present study, we observed that only 52% of steroid-
naive asthmatic subjects had elevated baseline sputum eosinophil 
levels. A higher sputum eosinophil percentage was correlated 
with a higher methacholine-induced airway hyperresponsiveness 
(lower PC20), but not with lung function (prebronchodilator 
FEV1). Sputum neutrophil percentage was not correlated with 
methacholine PC20 or prebronchodilator FEV1. In accordance 
with previous study results showing that AHR is associated with 
sputum eosinophil, but not sputum neutrophil levels [24], our 
findings suggest that sputum eosinophils are important mediators 
of AHR. However, an association between the numbers of sputum 
inflammatory cells (both eosinophils and neutrophils) and airway 
obstruction, which has been reported by several investigators [24, 
26], was not found in our study population. 
Most previous studies have shown that NEA is relatively steroid-
unresponsive and that sputum eosinophils are markers for a 
response to ICSs or systemic steroid therapy in asthmatics [17]. 
Several clinical trials have compared the treatment response 
to corticosteroids between steroid-naive NEA and EA patients. 
Green et al. [11] reported that compared with EA patients, NEA apallergy.org
Sputum eosinophilia and asthma
doi: 10.5415/apallergy.2011.1.1.16 23
REFERENCES
1.  Wenzel SE. Asthma: defining of the persistent adult phenotypes. 
Lancet 2006;368:804-13.
2.  Green RH, Brightling CE, Bradding P. The reclassification of asthma 
based on subphenotypes. Curr Opin Allergy Clin Immunol 
2007;7:43-50.
3.  Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: 
insights from clinical studies. Proc Am Thorac Soc 2009;6:256-9.
4.  Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the 
development of asthma. Nature 1999;402:B12-7.
5.  Djukanović R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, 
Howarth RH, Holgate ST. Mucosal inflammation in asthma. Am Rev 
Respir Dis 1990;142:434-57.
6.  Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, 
Kay AB, Durham SR. Prednisolone treatment in asthma. Reduction 
in the numbers of eosinophils, T cells, tryptase-only positive mast 
cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine 
gene expression within the bronchial mucosa. Am J Respir Crit Care 
Med 1996;153:551-6.
7.  Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the 
bronchi in mild asthma and after bronchial provocation. Am Rev 
Respir Dis 1989;139:806-17.
8.  Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander 
I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel FB. 
Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
9.  Grootendorst DC, Sont JK, Willems LN, Kluin-Nelemans JC, Van 
Krieken JH, Veselic-Charvat M, Sterk PJ. Comparison of inflammatory 
cell counts in asthma: induced sputum vs bronchoalveolar lavage 
and bronchial biopsies. Clin Exp Allergy 1997;27:769-79.
10.  Keatings VM, Evans DJ, O’Connor BJ, Barnes PJ. Cellular profiles in 
asthmatic airways: a comparison of induced sputum, bronchial 
washings, and bronchoalveolar lavage fluid. Thorax 1997;52:372-4.
11.  Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord 
ID. Analysis of induced sputum in adults with asthma: identification 
of subgroup with isolated sputum neutrophilia and poor response 
to inhaled corticosteroids. Thorax 2002;57:875-9.
12.  Turner MO, Hussack P, Sears MR, Dolovich J, Hargreave FE. 
Exacerbations of asthma without sputum eosinophilia. Thorax 
1995;50:1057-61.
13.  Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, 
Gibbs RL, Chu HW. Evidence that severe asthma can be divided 
pathologically into two inflammatory subtypes with distinct 
physiologic and clinical characteristics. Am J Respir Crit Care Med 
1999;160:1001-8.
14.  Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway 
inflammation in persistent asthma: evidence of neutrophilic 
inflammation and increased sputum interleukin-8. Chest 
2001;119:1329-36.
15.  Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: 
importance and possible mechanisms. Thorax 2002;57:643-8.
controller treatment is likely to be associated with the poor steroid 
response of neutrophilic airway inflammation mediated by IL-8, 
tumor necrosis factor a, or Th17 cells.
There are several limitations to our study. First, the size of the 
study population that completed the 24-month follow-up visits 
was small, possibly because the study subjects originated from an 
existing observational adult asthma cohort. Selection bias might 
have affected our results, although there were no significant 
differences in demographic and clinical characteristics between 
the follow-up and non-follow-up groups. Larger prospective 
studies are needed to corroborate these findings. Second, the 
study was not conducted with a fixed medication regimen, as 
discussed above. Third, the analysis of sputum eosinophilia was 
performed only once, at the baseline point of study entry, and 
was not repeated. Thus, the diagnosis of NEA or EA was based 
on a single sample of induced sputum. However, a recent study 
has indicated that a cut-off point of 3% eosinophils allows the 
presence of eosinophilia to be reliably determined from a single 
sputum sample [22].
Despite these limitations, our findings provide useful insights 
into the heterogeneity of asthma and its response to therapy. NEA 
patients showed poor lung function improvement compared 
with EA patients during the 24 months of follow-up in our Korean 
asthma cohort population. Thus, sputum eosinophils may predict 
the response to therapy, and NEA as a distinct clinical phenotype 
may relate to poor long-term treatment outcomes. 
ACKNOWLEDGEMENTS
The COREA Study Group includes the following investigators: 
Professor Sang-Heon Cho, Professor Heung-Woo Park, Professor 
Hye-Ryun Kang (Seoul National University), Professor Yoon-
Seok Chang, Professor Sae-Hoon Kim (Seoul National University 
Bundang Hospital), Professor Hee-Bom Moon, Professor You 
Sook Cho, Professor Tae-Bum Kim (University of Ulsan), Professor 
Byoung-Whui Choi (Chungang University), Professor Young-Joo 
Cho (Ewha Womans University), Professor Ho-Joo Yoon, Professor 
Sang-Heon Kim (Hanyang University), Professor Jung Won Park 
(Yonsei University), Professor An-Soo Jang (Soonchunhyang 
University), Professor Dong-Ho Nam (Ajou University).
This study was supported by a grant of the Korea Healthcare 
technology R&D project, Ministry of Health and Welfare, Republic 
of Korea (A102065).apallergy.org
Jung JW, et al.
Asia Pacific
allergy
doi: 10.5415/apallergy.2011.1.1.16 24
25.  Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, 
Bradding P, Wardlaw AJ, Pavord ID. Pathological features and inhaled 
corticosteroid response of eosinophilic and non-eosinophilic 
asthma. Thorax 2007;62:1043-9.
26.  Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green 
RH, Brightling CE, Wardlaw AJ, Pavord ID. Association between 
neutrophilic airway inflammation and airflow limitation in adults 
with asthma. Chest 2007;132:1871-5.
27.  Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, 
Paggiaro P. Low sputum eosinophils predict the lack of response 
to beclomethasone in symptomatic asthmatic patients. Chest 
2006;129:565-72.
28.  Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-
invasive markers of airway inflammation as predictors of oral steroid 
responsiveness in asthma. Thorax 2000;55:232-4.
29.  Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens 
HA. Accuracy of eosinophils and eosinophil cationic protein 
to predict steroid improvement in asthma. Clin Exp Allergy 
2002;32:1096-103.
30.  Pavord ID. Non-eosinophilic asthma and the innate immune 
response. Thorax 2007;62:193-4.
31.  McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar 
A, Henry A, Irvin CG, Piganelli JD, Ray A, Kolls JK. TH17 cells 
mediate steroid-resistant airway inflammation and airway 
hyperresponsiveness in mice. J Immunol 2008;181:4089-97.
32.  Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, 
Ceuppens JL. IL-17 mRNA in sputum of asthmatic patients: linking 
T cell driven inflammation and granulocytic influx? Respir Res 
2006;7:135.
33.  Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu 
Rev Physiol 2010;72:495-516.
16.  Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, 
Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and 
sputum eosinophil counts: a randomised controlled trial. Lancet 
2002;360:1715-21.
17.  Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and 
pathologic phenotype. J Allergy Clin Immunol 2007;119:1043-52.
18.  Kim TB, Park CS, Bae YJ, Cho YS, Moon HB. Factors associated with 
severity and exacerbation of asthma: a baseline analysis of the 
cohort for reality and evolution of adult asthma in Korea (COREA). 
Ann Allergy Asthma Immunol 2009;103:311-7.
19.  Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald 
M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, Pizzichini E, Sullivan 
SD, Wenzel SE, Zar HJ. Global strategy for asthma management and 
prevention: GINA executive summary. Eur Respir J 2008;31:143-78.
20.  Celli BR, MacNee W. Standards for the diagnosis and treatment of 
patients with COPD: a summary of the ATS/ERS position paper. Eur 
Respir J 2004;23:932-46.
21.  Sohn SW, Lee HS, Park HW, Chang YS, Kim YK, Cho SH, Kim YY, Min 
KU. Evaluation of cytokine mRNA in induced sputum from patients 
with allergic rhinitis: relationship to airway hyperresponsiveness. 
Allergy 2008;63:268-73.
22.  Simpson JL, McElduff P, Gibson PG. Assessment and reproducibility 
of non-eosinophilic asthma using induced sputum. Respiration 
2010;79:147-51.
23.  Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović 
R. The relationship between airways inflammation and asthma 
severity. Am J Respir Crit Care Med 2000;161:9-16.
24.  Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey 
HA, Segal M, Fahy JV. Relationship between airway inflammation, 
hyperresponsiveness, and obstruction in asthma. J Allergy Clin 
Immunol 2001;108:753-8.